Company research / ORMP

Oramed Pharmaceuticals Inc. (ORMP)

SEC name ORAMED PHARMACEUTICALS INC. · CIK 0001176309 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends around Dec 31

Partial revenue. In this company's filings, net income for the year ended 2025-12-31 is larger than reported revenue. The revenue it tags covers only part of its income (banks and REITs often tag only fee income this way, leaving out interest or rent), so it is not the company's whole top line. Margins on it are not computed, and it is left out of revenue rankings.

Key ratios (year ended 2025-12-31)

32.1%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-02

Headquarters locality: Jerusalem / New York City / Jerusalem · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312021-08-312020-08-312019-08-312018-08-312017-08-31
Revenuen/a$2.00Mn/a$1.34M$2.70Mn/a$2.70M$2.71M$2.70M$2.45M$2.46M
Cost of Revenuen/a$1.99Mn/an/an/an/an/an/a$90.0K-$86.0K$187.0K
Gross Profitn/a$13.0Kn/an/an/an/an/an/an/an/a$2.27M
R&D Expense$4.74M$6.38M$6.32M$8.97M$27.64Mn/a$20.99M$10.23M$13.52M$11.98M$10.28M
Operating Income-$14.52M-$15.09M-$12.78M-$15.77M-$40.60Mn/a-$24.22M-$11.76M-$14.63M-$13.53M-$10.77M
Net Income$174.87M$64.05M-$19.06M$5.09M-$36.56Mn/a-$22.99M-$11.51M-$14.36M-$12.73M-$10.48M
EPS (Diluted)n/a$1.50-$0.48$0.14-$0.94n/an/an/an/an/an/a
Total Assets$369.64M$230.86M$155.28M$220.55M$161.64M$177.82M$128.00M$44.63M$34.66M$47.40M$38.71M
Long-Term Debtn/an/an/an/a$25.0Kn/an/an/a$9.66M$11.39Mn/a
Shareholders' Equityn/a$199.74M$146.26M$163.82M$151.81M$166.45M$115.77M$32.88M$19.39M$31.11M$19.24M
Cash & Equivalents$15.24M$45.95M$54.42M$9.05M$40.46Mn/a$77.25M$19.30M$3.33M$5.00M$3.97M
Operating Cash Flow-$5.21M-$9.14M-$8.41M-$10.29M-$27.92Mn/a-$21.18M-$12.44M-$12.94M-$14.66M-$5.83M
Capital Expenditures$9.0K$9.0K$18.0K$254.0K$496.0Kn/a$375.0K$82.0K$15.0K$5.0K$7.0K
Free Cash Flow-$5.21M-$9.15M-$8.43M-$10.55M-$28.41Mn/a-$21.56M-$12.52M-$12.96M-$14.66M-$5.84M
Share Repurchasesn/a$4.74M$2.48Mn/an/an/an/an/an/an/an/a
Shares Outstanding41.31M39.28M39.92M40.34M39.56M38.16M35.29M23.68M17.38M17.37M13.67M
Dividends Per Sharen/a$0.25n/an/an/an/an/an/an/an/an/a
Weighted Average Diluted Sharesn/a42.42M40.85M40.57M39.00Mn/an/an/an/an/an/a
EPS (Basic)n/a$1.53-$0.48$0.14-$0.94n/an/an/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView